New MS treatment accepted by NICE

Eligible patients with multiple sclerosis (MS) must have the option to receive daclizumab (Zinbryta) on the NHS, NICE has ruled.

Daclizumab is recommended by NICE as an option for active relapsing–remitting MS. | SCIENCE PHOTO LIBRARY
Daclizumab is recommended by NICE as an option for active relapsing–remitting MS. | SCIENCE PHOTO LIBRARY

Daclizumab is recommended by NICE as an option for active relapsing–remitting MS in adults previously treated with disease-modifying therapy, and for rapidly evolving severe relapsing–remitting MS (defined as at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI), if alemtuzumab is contraindicated or otherwise unsuitable. 

Approval is contingent on the manufacturer continuing to provide the drug with the discount agreed in the patient access scheme.

NICE had previously rejected daclizumab for NHS use in initial draft guidance published in September 2016.

Launched earlier this year, daclizumab is a humanised monoclonal antibody that binds to CD25 and modulates IL-2 signalling, decreasing the number of activated T-cells that contribute to the nerve injury seen in MS.


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases